How Chronic SIBO May Actually Be Gut Parasites
In a Nutshell
Chronic SIBO and treatment-resistant GI symptoms may actually stem from undetected parasites like Giardia, Blastocystis, and Cryptosporidium, which damage intestinal villi, impair enzyme production, and cause long-term food intolerances, fatigue, and histamine issues. Standard PCR stool tests frequently miss parasites, so clinical diagnosis relies on symptom history, risk factors like water exposure, and specialized testing like ParaWellness, with treatment often requiring pharmaceutical antiparasitics like nitazoxanide or the Yu-Klinghardt protocol rather than herbal agents alone. Addressing parasites before SIBO, candida, or MCAS interventions yields faster food tolerance improvements and breaks the cycle of repeated ineffective treatments.
These notes were generated by AI and may contain inaccuracies.
A large data set from roughly 400,000 stool samples found parasites present in roughly 20% of those with symptoms. Exposure to Giardia was associated with perceived food intolerances 3 years after giardiasis. Roughly 30% developed chronic fatigue after Giardia, which is a common waterborne parasite, and that fatigue persisted up to 6 years later.
The statement "Everyone has a parasite" is vastly hyperbolic or overblown, but infections do occur in some people, and identification and treatment of a parasite can be very helpful for those with a true infection. The clinical team sees patients and collects data on parasites.
Michael Ruscio is a doctor in private practice, adjunct professor, and clinical researcher in integrative and functional medicine. Dr. Scott S. Digliozia is a doctor in the practice and functions as the director of clinical care, co-authoring the previous paper on SIBO biofilms. Dr. Jake Von Feldt is the research manager and driving force behind many research studies.
Dr. Von Feldt notes that patients who have already tried treating SIBO, Candida, or histamine intolerance and are stuck in that loop have seen good results with treating parasites. Dr. Digliozia has seen that addressing parasites is more often than not the biggest needle mover for improving food tolerance, and patients improve their food tolerance pretty quickly after the parasite was addressed.
There is not a great test that can tell you definitively if you have or don't have parasites and which ones you do have. The team uses testing plus symptoms to create a mosaic of risk and treats upon the aggregate risk calculation rather than going exclusively by test results.
Giardia is the most common parasite seen on stool tests. It is picked up from contaminated water, including in the United States from unfiltered water or swimming in natural bodies of water. Giardia is also known as "beaver fever" because beaver feces is one contamination vector. Even if you don't drink the water, getting some in your mouth while swimming can be enough to acquire Giardia.
Cryptosporidium is a fairly common parasite seen on stool testing that presents mainly with diarrhea. Over 800,000 cases per year are reported in the US, and it is chlorine resistant, so it can be picked up at pools.
Pinworms affect up to 20% of children. Other parasites mentioned include Entamoeba histolytica (very pathogenic), Blastocystis hominis (gray area - sometimes problematic, sometimes not), Dientamoeba fragilis, hookworms, liver flukes, and tapeworms.
Giardia in the small intestine cuts the villi in half, reducing enzymes needed to break down carbohydrates and fats. This leads to malabsorption of lactose, sucrose, and other carbohydrate and fat compounds, causing gas and bloating when eating dairy, broccoli, or beans. Giardia also causes inflammation in the small intestine that can affect motility, leading to slowed motility and increased risk of SIBO.
A 2018 observational study with nearly 900 patients found that those with past parasite exposure had increased odds of constipation, dyspepsia, indigestion, and GERD or heartburn. A 2014 study with 1,200 patients with prior Giardia infection found that 30% developed chronic fatigue after the infection that persisted for up to 6 years.
Studies link Blastocystis to chronic urticaria or chronic hives, a common symptom of MCAS or histamine-related symptoms. In one study, metronidazole, paromomycin, and tinidazole were the most prescribed drugs for single Blastocystis infection, and urticaria and other cutaneous symptoms resolved after treatment, typically within 7-10 days.
One patient tested positive for Blastocystis on parasite testing and was treated with paromomycin without symptom shift, but rifaximin for SIBO put his urticaria into remission for a couple months. Another patient developed fever, headache, and bilateral swelling above eyebrows after visiting a strawberry field, suggestive of Botrytis cinerea (gray mold or wine grower's lung) rather than a parasite.
In the United States, the epidemiology of parasites is unknown because testing is not always reliable, can give false negatives, and accurate prevalence data is lacking. The history is equally important to testing - understanding when symptoms started, what triggered them (travel abroad, camping trip, food poisoning), and listening to the patient's story helps determine if a parasite might be the root cause.
Patients who are doing all the right things - eating healthy, trying probiotics and natural antimicrobials like oregano oil, sleeping well, exercising - but whose health is not great if they deviate at all are candidates for possible parasitic infection. The team is open-minded about considering parasites, and patients often feel relief that their symptoms are being taken seriously rather than being brushed off as IBS.
Early in his career, Michael Ruscio was gung-ho about parasites after having a pathogenic amoeba (Entamoeba histolytica) in college. However, after multiple negative tests, he concluded that SIBO and fungus were more likely underlying causes. Dr. Tomy Dempsey introduced the ParaWellness testing approach to the practice.
Parasite testing has shown roughly 30% positive rates, which aligns with data from a large 400,000 patient cohort study showing approximately 20% prevalence. Parasites represent a meaningful subset of patients that can be pre-qualified through clinical history before proceeding to testing.
Two primary methods exist for stool parasite testing. The ova and parasite exam (O&P exam) involves direct microscopic examination of stool samples to identify parasite eggs, organisms, or cysts, but results depend heavily on the examiner's skill and consistency. PCR-based testing detects genetic sequencing of parasites and offers high sensitivity, though panels only detect organisms specifically included in the panel. PCR testing typically does not include helminths (worms).
Research indicates that two stool samples provide better diagnostic yield than one due to intermittent parasite shedding. Patients collect samples from separate bowel movements across different days, with the two vials sent to the laboratory together. While two samples appear superior to one, the rigor of microscopic examination may be equally important as sample quantity. The cost-benefit trade-off becomes relevant when considering three samples versus two.
Direct comparisons between ParaWellness (single stool) and Parasitology Center (two-day) testing are being conducted on individual patients to determine relative performance. The test yielding the most positives is not necessarily the best test, requiring systematic evaluation rather than confirmation bias.
A patient tested positive for Giardia and Cryptosporidium on ParaWellness testing after three different functional medicine PCR-based stool tests returned negative results. The same patient also tested negative on Parasitology Center testing. Treatment with a specific anti-parasitic pharmaceutical resulted in resolution of chronic loose stool within the first week. This patient had previously undergone months of natural antimicrobial agents without improvement.
Empirical pharmaceutical anti-parasitics have some research support for patients with unresolved chronic symptoms when testing is inconclusive. Side effect profiles of pharmaceutical anti-parasitics are often similar to those of natural agents like oregano. Side effects such as reflux, indigestion, and loose bowels appear on labels for both pharmaceutical and natural treatments.
A patient developed Giardia after travel to Asia ten years ago. Standard laboratory testing confirmed Giardia and treatment cleared the organism on follow-up testing, but symptoms persisted. Multiple functional medicine PCR-based stool tests were negative. ParaWellness testing was positive, and herbal treatment initially appeared to resolve symptoms, but regression occurred. This highlights the potential need for pharmaceutical interventions in addition to herbal approaches.
Pharmaceutical anti-parasitics may show less regression compared to herbal treatments, possibly due to more complete organism elimination allowing the immune system to manage remaining load. Multiple rounds of treatment may be necessary for complete resolution. Data tracking through systematic collection and analysis has revealed treatment effects not apparent through casual observation, as demonstrated by a biofilm study showing 30-point greater gas reduction when antibiofilm agents were added to herbal antimicrobials.
Protozoa including Blastocystis, Cryptosporidium, and Giardia appear more frequently on stool testing than helminths. However, patients sometimes respond to anti-worm medications despite negative stool testing, possibly because worms shed less readily in stool samples.
Blood antibody panels for worms and amoebas, previously used but later abandoned, are being reconsidered. Antibodies exist for Ascaris lumbricoides, Taenia solium, and Entamoeba histolytica that may detect organisms not visible in stool testing. A patient case demonstrated elevated eosinophils and hives progressing to severe muscle weakness and pain, consistent with helminth infection affecting muscle tissue where stool testing would be ineffective.
Parasites should be addressed before SIBO or candida when chronic gastrointestinal symptoms persist despite treatment. Parasites appear more resistant to natural agents, and clearing parasitic infection may resolve or simplify subsequent SIBO treatment. Patients with treatment-resistant GI symptoms, histamine intolerance, or mast cell activation should be evaluated for parasites.
Highly reactive patients sensitive to supplements, foods, smells, and mold may have mast cell activation syndrome rather than parasites. Treating such patients for parasites risks significant reactions. Mast cell reactivity should be calmed before initiating parasite treatment. Some patients may have their symptoms fully resolved by addressing mast cell activation alone without parasite treatment.
Individual response to anti-parasitic treatment cannot be reliably predicted. Some patients tolerate treatments well despite apparent mast cell activation risk, while others experience unexpected reactivity. Treatment requires attentive navigation based on individual response patterns.
Die-off reactions typically present as flu-like symptoms including fatigue, brain fog, joint pain, and manageable gastrointestinal upset. Mast cell reactions cause more severe symptoms that leave patients out of commission. One patient experienced worsened diarrhea throughout a 30-day anti-parasitic treatment but achieved complete resolution of symptoms after completing the course. Treatment response patterns generally fall into three categories: immediate improvement, brief die-off followed by improvement, or symptoms throughout treatment with improvement only after completion.
When patients receive antimicrobials, some experience the intended therapeutic effect while simultaneously experiencing irritation to gastrointestinal tissue. This irritation can mask benefits until the offending antimicrobial is removed. Some patients show no improvement at all. If patients don't improve, re-evaluation of the root cause is necessary.
For patients with longer-duration GI symptoms, stool test results may represent only the tip of the iceberg from a parasite perspective. Supporting data indicates that after antihelminth or antiworm treatment, repeat stool tests may reveal new parasites that were not initially detected. This may represent unmasking of dormant parasites or increased activity once competing organisms are removed.
A Cambodian immigrant study documented amoebic infections appearing after worm treatment. Similar patterns have been observed where parasite load increased on second testing compared to first testing. Research tracking in integrative functional medicine settings is limited, making systematic data collection essential for understanding these patterns.
The theory proposes that during infection, intestinal villi become blunted while crypts between villi deepen. This allows infections to foster in deeper crypts. As treatment progresses, villi heal and crypts become shallower, potentially pushing previously hidden infections to the surface. This mechanism remains unproven but is consistent with clinical observations.
Follow-up stool testing helps determine if additional treatment is needed. The pattern of initial improvement followed by regression may indicate incomplete treatment rather than treatment failure. Despite the inconvenience and cost of stool testing (averaging $300), follow-up testing is considered worthwhile in many situations.
A study examined patients who became ill after traveling but had negative stool tests. When given empiric antiparasitic treatments based on history and symptoms, remarkable improvements occurred: 68% improvement in energy, 69% improvement in GI symptoms, and 37% reported full recovery within a few weeks.
The protocol consisted of tinidazole (an anti-protozoan medication targeting Giardia and Blastocystis) for two days, plus another anti-worm medication for five days, totaling a seven-day protocol. Extreme fatigue was one of the most common symptoms, consistent with earlier data linking Giardia to chronic fatigue syndrome.
Patients with longer symptom duration (approximately 3 years) were less likely to respond to the medication protocol. Those with symptoms for roughly one year were more likely to respond. This suggests longer treatment duration may be needed for those with extended symptom histories or higher infection burden.
Two scoring systems are used: the Wellness Score (0-100 self-rated feeling scale) adopted from a Johns Hopkins study on high-dose cromolyn, and the PHQ-15, a validated 15-question symptom inventory measuring quality of life. These tools enable systematic tracking for potential publication and peer review.
The approach emphasizes interrogating positions rather than accepting conventional wisdom. This includes pressure-testing ideas about probiotics, antifungals, and other treatments. The goal is to tear down bad ideas while bringing the best ideas to patients through systematic evaluation.
An 2018 study examined anti-worm medication impact on work capacity in African women. Regardless of stool test results, women received either placebo or albendazole. Only those with confirmed parasites benefited from albendazole. Those without parasites on stool testing showed no benefit. The study measured work capacity rather than GI symptoms.
Public health research establishes that community parasite burden is inversely proportional to community output. This principle informed the African women's study, where low sanitation conditions suggested high parasite burden, warranting treatment to assess impact on work capacity.
The CDC endorses albendazole, ivermectin, and praziquantel for refugees as preventative measures without stool testing. These medications are part of the planned protocol. For Babesia, travelers to malaria-endemic areas receive atovaquone prophylactically, providing precedent for therapeutic trials even with negative testing.
Atovaquone appears well-tolerated for preventative use despite concerning side effect lists. Similarly, ibuprofen has extensive side effects but is generally well-tolerated. Internet research, particularly Reddit, can create unnecessary alarm through individual case reports that may not be relevant to specific situations.
Treatment is conceptualized in three phases: foundation for gut health, natural antimicrobials/antiparasitics, and pharmaceuticals. The foundation includes basic lifestyle factors rather than genetic, adrenal, or food allergy testing results.
A 20-year-old RCT examined Saccharomyces boulardii in Giardia patients. Those receiving only metronidazole had 17% remaining Giardia cysts after one month. Those receiving metronidazole plus Saccharomyces boulardii had 0% remaining cysts. Another study showed Saccharomyces boulardii was more effective than metronidazole for Blastocystis.
Diet recommendations are based on individual lived experience rather than testing. Key factors include determining personal tolerance to dairy, vegetables, and carbohydrate levels. Basic inputs for gut and immune health include adequate sleep, exercise, stress management, and time in nature.
The Biotic Clear protocol, originally published for SIBO biofilm treatment, has been observed to clear parasites clinically. This herb combination provides antiparasitic, antibacterial, and antifungal effects. The Great Plains protocol includes step three as the antimicrobial phase after gut fortification.
Artemisia (artemisinin) serves as a synergist with Biotic Clear, showing antiprotozoal activity against Blastocystis, Giardia, and Cryptosporidium. It also demonstrates anti-inflammatory effects and has research supporting its use in inducing or maintaining remission in inflammatory bowel disease. It possesses potent antifungal properties.
N-acetylcysteine (NAC) functions as a potent antioxidant and mucolytic agent. The mucolytic effect may help eradicate parasites that burrow into the gut mucus layer by allowing antimicrobials to penetrate more deeply. A piglet study showed NAC improved gut lining health after LPS-induced damage and increased nutrient absorption.
A Tulane study by Kiki Zau and colleagues administered 15g daily of L-glutamine to post-infectious IBS patients, finding 80% symptom improvement. This is relevant given the overlap between post-infectious IBS and suspected parasite cases.
Multiple studies demonstrate Vitamin A reduces parasitic infections compared to placebo. The mechanism is likely immune system mediated rather than direct antiparasitic action.
A 2018 meta-analysis found that among people developing post-infectious IBS, approximately 42% of cases were parasite-related compared to 14% bacterial. This suggests post-infectious IBS may be parasite-driven more often than bacterial.
The elemental diet serves as a tool to reduce gut inflammation, particularly when food reactivity is present. It provides a simple method to calm symptoms and can serve as a foundation for layering additional therapies.
An older 1975 trial found berberine as effective as three other drugs it was compared to. A 2000 trial using oregano showed notable improvement in symptoms for protozoa including Blasto, Entamoeba, and Endolimax nana.
The Biotic Clear protocol was published in the journal Cureus and demonstrated remarkable reduction in SIBO using berberine, oregano, and other herbal antimicrobial agents in conjunction with an anti-biofilm agent. The protocol uses Biota Dissolve as the anti-biofilm agent, with Biocidin 1A and 1B for month 1, transitioning to Biocidin 2A and 2B for month 2.
This protocol is routinely observed to clear certain parasites including Blasto and Giardia, even when they don't frequently appear positive on stool tests.
The complete foundational protocol includes:
- Elemental diet to reset, calm down, heal, and rest
- Probiotics, which synergize with antiparasitics
- Gut rebuild nutrient formula containing vitamin A and glutamine for leaky gut and gut lining support
- Biocidin clear protocol
Anytime killing interventions (antiparasitic, antifungal, anti-SIBO) have been studied synergistically with probiotics, the effect is better with less side effects and increased clearance of the infection being treated.
The treatment hierarchy is foundation first, herbal second, then pharmaceuticals if patients are still not responding. Some patients prefer the mentality of bringing out the big guns immediately, while others prefer more naturalistic and gentle approaches. Good clinicians should discuss options with patients, presenting pros and cons of each approach and allowing patients to decide what they're most comfortable with.
Dr. Steven Wangen, a well-known GI specialized naturopathic doctor, stated: "I do not doubt that there are herbal medicines with strong antiparasitic properties, but the reality is that I have not had great success eradicating these parasites with natural medicines."
Dr. Ilana Gurevich, another naturopathic GI specialist, stated: "I would love someone to give me an herbal protocol that works. It's a bummer to have to use the medications, but they actually work."
Prescriptions appear to work better for parasites, working quicker and more effectively in clinical experience.
The field needs better follow-up data. Leonard Weinstock is noted as having excellent follow-up data due to his insurance-based model. What appears as notable response from pharmaceuticals may not be durable without proper follow-up at 2, 3, 4, 6, and 8 months later. Some patients on pharmaceutical protocols have experienced regression requiring retreatment.
The Yu-Klinghardt protocol (UK protocol) is based on Dr. Simon Yu's original sequence of anti-parasitic medications, modified by Dietrich Klinghardt, and further modified. This sequential step-by-step protocol targets specific categories of parasites and covers most common parasites that could be present, addressing the issue of false negatives on stool testing.
Step one uses praziquantel paired with cimetidine for 3 days. Cimetidine, an antacid, increases blood levels of praziquantel making it more effective. Praziquantel primarily targets tapeworms and liver flukes. There is flexibility in duration based on tolerance - if someone experiences significant die-off, they may stop at 2 days rather than pushing to 3.
Step two combines albendazole and ivermectin for 2 weeks, which appears most effective for killing roundworms. This duration is longer than standard treatment (single dose or up to 3 days). Data exists showing patients using these medications for 4 months daily or up to 15 months with either mild, infrequent, or no side effects, supporting that 2 weeks is a safe duration.
If die-off is too significant, the protocol can be broken into 3-5 days on, one week off, then repeated.
These are recommendations to discuss with healthcare providers, not endorsements for self-treatment or purchasing prescriptions online independently.
Step three repeats step one for a second hit on flukes and tapeworms.
Step four uses nitazoxanide (Alinia) for approximately 3 weeks. This medication primarily targets Giardia, Cryptosporidium, Blastocystis, some worms, and has activity against SIBO. Nitazoxanide is often observed to be the most effective medication in the protocol.
At regular pharmacies like CVS or Walgreens, Alinia can cost roughly $3,000 for a 30-day supply. CareFirst Specialty Pharmacy in New Jersey offers nitazoxanide for approximately $125. GoodRx coupons can reduce costs significantly, with examples of $150 pricing.
Two main modifications were made to the Yu-Klinghardt protocol:
- Removed pyrantel pamoate as it was considered redundant
- Moved to body weight adjusted dosing (milligrams per kilogram of weight) to prevent lighter patients (100-130 lbs) from being overdosed and heavier patients (200+ lbs) from being underdosed
A younger male presented with abdominal pain, loose floating stools, primary food reactivity to beans and dairy, and fat intolerance. He had a documented Giardia infection 4-5 years prior. Herbal antimicrobials previously tried made no difference.
Power Wellness stool test found Blastocystis, Endolimax, and Entamoeba coli, but no Giardia. Nitazoxanide treatment resulted in resolution of loose stool and abdominal pain within 4-5 days. Within one month, he regained tolerance to dairy, beans, and increased fat intake.
A male developed chronic diarrhea and multiple symptoms after food poisoning in Mexico that affected his entire family. He tested positive for Giardia on Pearl Wellness testing. After 16 days of nitazoxanide (stopped early due to vague unwellness), symptoms improved including:
- Food tolerance (reintroduced eggs, bacon, pasta)
- Healthier hair and skin
- Lessened fingernail issues
- Improved libido
- Reduced need for Zyrtec
- Improved runny nose
- Improved sleep
- Improved shortness of breath
- Reduced chronic left ear pressure
- Decreased head and neck pressure
A patient tested positive for Giardia through Pearl Wellness testing. Treatment with nitazoxanide was initiated, but follow-up testing showed Giardia remained present. The patient then tried tinidazole, another medication used specifically for Giardia treatment. After completing the tinidazole course, the Giardia cleared completely according to ParaWellness testing, resulting in a totally negative test result with no positive findings.
Despite successful clearance of the Giardia, the patient did not experience additional symptom improvement. While there was noticeable improvement from earlier interventions, the patient was not completely out of the woods, and additional treatment approaches were being pursued.
When considering whether to pursue a full antiparasitic protocol after initial treatment failure, the clinical approach involves evaluating the strength of signals for different conditions. In this case, there was a pretty strong clinical signal for Candida, leading to that treatment route first. The next step would possibly involve circling back to the full protocol if other angles don't produce adequate response.
The key question being tracked is whether nitazoxanide or Alinia by itself is sufficient, or whether starting with the entire protocol is more effective. The approach involves starting with narrower treatment and moving to broader protocols based on response, though the optimal sequence remains under investigation.
For patients with chronic symptoms lasting more than 6 months, definitely over a year, or certainly a few years, who have already done foundational interventions without improvement, a systematic framework is applied. The approach addresses two primary factors: immune system dysfunction and polymicrobial infection, where multiple infections are likely present simultaneously.
The goal is to modulate chronic inflammation, histamine intolerance, and mast cell activation while treating the underlying infections that trigger these responses in a self-perpetuating cycle.
The general sequence for addressing chronic conditions follows this progression:
- Immune system and MCAS dysfunction support runs parallel throughout the entire sequence, as this tends to be important for all patients
- Start with gut health interventions, generally flowing from parasites first, then addressing SIBO and fungus
- Consider mold exposure, with particular focus on identifying people who are colonized with mold rather than simply exposed through their environment
- Address Lyme disease family or vector-borne infections last, including babesia, Borrelia Lyme, and Bartonella
The rationale for sequencing vector-borne infections last includes the possibility that treating other factors first may improve immune system health enough that these infections don't require treatment. Additionally, these infections tend to be the most evasive of the immune system, making it beneficial to prime the patient and improve overall health before addressing them.
The final step in the framework involves mitochondrial support, cell membrane support, and other restorative therapies. This systematic approach helps organize and prioritize interventions rather than addressing every component simultaneously, which can feel overwhelming and is less efficient.
Not everybody has parasites, but they can be present in certain cohorts of patients. It's important to consider parasites in cases of chronic GI symptoms. The approach involves using available testing methods while also listening carefully to patients and understanding what they've previously tried and whether those interventions helped or not. Prior treatment response provides important clues about whether parasites might be involved.
The goal is to find the middle ground between dismissing parasites entirely and assuming everyone needs regular parasite cleanses. The approach involves ongoing data collection to better understand how to assess who does versus who doesn't have parasites.
Many patients find themselves in a cycle of repeatedly treating SIBO, fungus, mold, and candida without addressing the parasite component. When the parasite piece has been overlooked and is then addressed clinically, significantly more patients have been helped than previously possible.
The comprehensive discussion covered common parasites, acquisition methods, telltale symptoms, testing options, foundational support, natural treatment options, and pharmaceutical interventions. Recommended resources include finding a good integrative, naturopathic, or functional doctor. The book "Healthy Gut Healthy You" provides a stepwise approach to many of the discussed concepts. The clinic remains available for consultation when needed.
Keep Dr. Michael Ruscio, DC, DNM in your library
Save the videos and channels worth coming back to, and find them again in one place.
